Precision Medical Ventures, Inc. dba RevealDx

RevealDx is a Seattle-based software company delivering FDA-cleared AI-powered lung cancer decision support software. The company has developed RevealAI-Lung, an advanced radiomics and artificial intelligence platform for non-invasive lung nodule characterization and malignancy risk assessment. The platform generates a Malignancy Similarity Index (mSI™) score to help clinicians confidently identify lung cancer type without invasive biopsies or surgeries. The software features single-click operation with results displayed within seconds, enabling actionable radiomic insights while reducing unnecessary procedures and associated healthcare costs. RevealDx holds FDA clearance and MDR certification, positioning it as a leader in AI tools for precision lung cancer diagnosis and improved patient outcomes.